Trevor Dorkin

Dr. Trevor Dorkin is a researcher at Newcastle University, affiliated with the Faculty of Medical Sciences and the Institute of Cellular Medicine. He has made sustained contributions to urology, particularly in clinical urology, urological oncology, and surgical outcomes. His work spans from molecular pathology to health services research and clinical guidelines.

Research Interests: His primary fields include Urology, Prostate Cancer, Urethral Stricture, Testicular Torsion, Laparoscopic Surgery, and Molecular Pathology. His research integrates clinical practice with molecular analysis, aiming to improve diagnostic accuracy and treatment outcomes.

The recent publications, including the 2022 BURST-BAUS consensus document and the 2021 OPEN trial cost-effectiveness analysis, reflect a strong trend toward evidence-based practice, guideline development, and health economic evaluation in urological care. Earlier works focus on molecular mechanisms in prostate cancer, showing a long-standing interest in oncological pathways and biomarkers.

Dr. Dorkin has collaborated extensively with leading urological researchers such as Professor Christopher Harding, Rob Pickard, and Professor David Neal. While no formal awards are listed, his involvement in high-impact clinical trials and systematic reviews underscores his role in advancing urological science.

Advising and Grants: There is no explicit mention of students or grant funding in the provided text. However, his repeated involvement in multi-center studies suggests participation in collaborative research networks and likely access to external funding.

Labs and Teams: Dr. Dorkin appears to be part of a broader urological research group at Newcastle University, contributing to both clinical and molecular research streams. His work with the BURST-BAUS group indicates active participation in national consensus-building initiatives in urology.